Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea’s Samsung Biologics Halts Rituxan Biosimilar Trials To Meet U.S, EU Standards

This article was originally published in PharmAsia News

Executive Summary

Samsung Biologics halts ongoing clinical trials across 16 countries for its Rituxan biosimilar as it seeks clarity on emerging regulatory guidelines by U.S. FDA.

Advertisement

Related Content

Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Biosimilar Interchangeability: Stakeholders Want More FDA Guidance, Fewer Hurdles
Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now
Korea's Celltrion In Deal With U.S.-based Hospira For Biogeneric Sales; M&A Hinted At

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC079590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel